Oruka Therapeutics (ORKA) Free Cash Flow (2010 - 2026)
Oruka Therapeutics' quarterly Free Cash Flow came in at -$23.7 million in Q1 2026, down 13.26% year-on-year from -$27.3 million in Q1 2025, and down 4.31% quarter-over-quarter from -$22.7 million in Q4 2025.
Oruka Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$23.7 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 13.26% year-over-year to -$23.7 million; the trailing twelve-month figure through Mar 2026 stood at -$91.2 million (down 16.06% YoY), and the FY2025 full-year result was -$88.4 million, down 52.38% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$23.7 million, down from -$22.7 million in the prior quarter.
- The five-year high for Free Cash Flow was -$168000.0 in Q1 2024, with the low at -$27.8 million in Q3 2024.
- Average Free Cash Flow over 5 years is -$10.9 million, with a median of -$4.3 million recorded in 2022.
- Year-over-year, Free Cash Flow soared 89.47% in 2024 and sank 12329.76% in 2025.
- Tracing ORKA's Free Cash Flow over 5 years: stood at -$1.5 million in 2022, then advanced by 29.32% to -$1.1 million in 2023, then plunged by 1683.71% to -$18.8 million in 2024, then decreased by 20.37% to -$22.7 million in 2025, then fell by 4.31% to -$23.7 million in 2026.
- The last three Free Cash Flow figures came in at -$23.7 million (Q1 2026), -$22.7 million (Q4 2025), and -$21.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | -23.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.65 Mn |
| Mar 31, 2026 | -23.65 Mn |
| Dec 31, 2025 | -22.67 Mn |
| Dec 31, 2025 | -22.67 Mn |
| Sep 30, 2025 | -21.70 Mn |
| Sep 30, 2025 | -21.70 Mn |
| Jun 30, 2025 | -23.17 Mn |
| Jun 30, 2025 | -23.17 Mn |
| Mar 31, 2025 | -20.88 Mn |
| Mar 31, 2025 | -20.88 Mn |
| Dec 31, 2024 | -18.84 Mn |
| Dec 31, 2024 | -18.84 Mn |
| Sep 30, 2024 | -27.82 Mn |
| Sep 30, 2024 | -27.82 Mn |
| Jun 30, 2024 | -11.03 Mn |
| Jun 30, 2024 | -11.03 Mn |
| Mar 31, 2024 | -168,000.00 |
| Mar 31, 2024 | -168,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2023 | -1.06 Mn |
| Sep 30, 2023 | -1.67 Mn |
| Sep 30, 2023 | -1.67 Mn |
| Jun 30, 2023 | -694,000.00 |
| Jun 30, 2023 | -694,000.00 |
| Mar 31, 2023 | -1.60 Mn |
| Mar 31, 2023 | -1.60 Mn |
| Dec 31, 2022 | -1.49 Mn |
| Dec 31, 2022 | -1.49 Mn |
| Sep 30, 2022 | -2.50 Mn |
| Sep 30, 2022 | -2.50 Mn |
| Jun 30, 2022 | -2.62 Mn |
| Jun 30, 2022 | -2.62 Mn |
| Mar 31, 2022 | -4.30 Mn |
| Mar 31, 2022 | -4.30 Mn |
| Dec 31, 2021 | -4.95 Mn |
| Dec 31, 2021 | -4.95 Mn |
| Sep 30, 2021 | -4.90 Mn |
| Sep 30, 2021 | -4.90 Mn |
| Jun 30, 2021 | -3.73 Mn |
| Jun 30, 2021 | -3.73 Mn |
| Mar 31, 2021 | -5.23 Mn |
| Mar 31, 2021 | -5.23 Mn |
| Dec 31, 2020 | -3.01 Mn |
| Dec 31, 2020 | -3.01 Mn |
| Sep 30, 2020 | -2.00 Mn |
| Sep 30, 2020 | -2.00 Mn |
| Jun 30, 2020 | -1.05 Mn |
| Jun 30, 2020 | -1.05 Mn |
| Mar 31, 2020 | -1.69 Mn |
| Mar 31, 2020 | -1.69 Mn |
| Dec 31, 2019 | -1.16 Mn |
| Dec 31, 2019 | -1.16 Mn |
| Sep 30, 2019 | -887,000.00 |
| Sep 30, 2019 | -887,000.00 |
| Jun 30, 2019 | -1.19 Mn |
| Jun 30, 2019 | -1.19 Mn |
| Mar 31, 2019 | -1.57 Mn |
| Mar 31, 2019 | -1.57 Mn |
| Dec 31, 2018 | -1.34 Mn |
| Dec 31, 2018 | -1.34 Mn |
| Sep 30, 2018 | -1.58 Mn |
| Sep 30, 2018 | -1.58 Mn |
| Jun 30, 2018 | -2.25 Mn |
| Jun 30, 2018 | -2.25 Mn |
| Mar 31, 2018 | -3.07 Mn |
| Mar 31, 2018 | -3.07 Mn |
| Dec 31, 2017 | -4.20 Mn |
| Dec 31, 2017 | -4.20 Mn |
| Sep 30, 2017 | -3.97 Mn |
| Sep 30, 2017 | -3.97 Mn |
| Jun 30, 2017 | -4.96 Mn |
| Jun 30, 2017 | -4.96 Mn |
| Mar 31, 2017 | -4.34 Mn |
| Mar 31, 2017 | -4.34 Mn |
| Dec 31, 2016 | -3.85 Mn |
| Dec 31, 2016 | -3.85 Mn |
| Sep 30, 2016 | -3.74 Mn |
| Sep 30, 2016 | -3.74 Mn |
| Jun 30, 2016 | -3.53 Mn |
| Jun 30, 2016 | -3.53 Mn |
| Mar 31, 2016 | -3.88 Mn |
| Mar 31, 2016 | -3.88 Mn |
| Dec 31, 2015 | -2.62 Mn |
| Dec 31, 2015 | -2.62 Mn |
| Sep 30, 2015 | -2.40 Mn |
| Sep 30, 2015 | -2.40 Mn |
| Jun 30, 2015 | -2.40 Mn |
| Jun 30, 2015 | -2.40 Mn |
| Mar 31, 2015 | -3.12 Mn |
| Mar 31, 2015 | -3.12 Mn |
| Dec 31, 2014 | -1.89 Mn |
| Dec 31, 2014 | -1.89 Mn |
| Sep 30, 2014 | -2.08 Mn |
| Sep 30, 2014 | -2.08 Mn |
| Jun 30, 2014 | -1.76 Mn |
| Jun 30, 2014 | -1.76 Mn |
| Mar 31, 2014 | -3.69 Mn |
| Mar 31, 2014 | -3.69 Mn |
| Dec 31, 2013 | -1.88 Mn |
| Dec 31, 2013 | -1.88 Mn |
| Sep 30, 2013 | -1.69 Mn |
| Sep 30, 2013 | -1.69 Mn |
| Jun 30, 2013 | -984,000.00 |
| Jun 30, 2013 | -984,000.00 |
| Mar 31, 2013 | -773,000.00 |
| Mar 31, 2013 | -773,000.00 |
| Dec 31, 2012 | -670,000.00 |
| Dec 31, 2012 | -670,000.00 |
| Sep 30, 2012 | -775,000.00 |
| Sep 30, 2012 | -775,000.00 |
| Jun 30, 2012 | -977,000.00 |
| Jun 30, 2012 | -977,000.00 |
| Mar 31, 2012 | -1.66 Mn |
| Mar 31, 2012 | -1.66 Mn |
| Dec 31, 2011 | -1.25 Mn |
| Dec 31, 2011 | -1.25 Mn |
| Sep 30, 2011 | -1.68 Mn |
| Sep 30, 2011 | -1.68 Mn |
| Jun 30, 2011 | -2.11 Mn |
| Jun 30, 2011 | -2.11 Mn |
| Mar 31, 2011 | -1.94 Mn |
| Mar 31, 2011 | -1.94 Mn |
| Dec 31, 2010 | -1.14 Mn |
| Dec 31, 2010 | -1.14 Mn |
| Sep 30, 2010 | -2.01 Mn |
| Sep 30, 2010 | -2.01 Mn |